Epilepsy Talk

Increased Birth Defect Risks in Two FDA-Approved Epilepsy Medications | October 20, 2011

Two epilepsy drugs – Lamictal and Keppra – which are currently listed in category C may be dangerous to a fetus and should be listed in category D, according to new data. The difference between the categories is that D shows evidence of risk, but the benefits outweigh the risks. While category C is indicated for drugs that have shown to be harmful in animal studies…

http://central-pennsylvania.injuryboard.com/fda-and-prescription-drugs/increased-birth-defect-risks-in-two-fdaapproved-epilepsy-medications.aspx?googleid=295210

Posted in Epilepsy, Medication Issues, News, Research
Tags: , , , , ,

2 Comments »

  1. mkfarnam's avatar

    How did or do they determine that “possible” temporary benefits, out weigh permenant risks?

    Like

    Comment by mkfarnam — October 21, 2011 @ 1:24 AM

    Reply
  2. Phylis Feiner Johnson's avatar

    Linguistics!

    Like

    Comment by Phylis Feiner Johnson — October 21, 2011 @ 1:44 PM

    Reply

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

    About the author

    Phylis Feiner Johnson

    Phylis Feiner Johnson

    I've been a professional copywriter for over 35 years. I also had epilepsy for decades. My mission is advocacy; to increase education, awareness and funding for epilepsy research. Together, we can make a huge difference. If not changing the world, at least helping each other, with wisdom, compassion and sharing.

    View Full Profile →

    To receive Epilepsy Talk articles FREE, simply go to the bottom of the right column, enter your email address and click on "Follow"

    Join 3,107 other subscribers
    Follow Epilepsy Talk on WordPress.com